Bisphosphonates for the prevention of fractures in osteogenesis imperfecta: Meta-analysis of placebo-controlled trials

Journal of Bone and Mineral Research

Volumn 30, Issue 5, 2015, Pages 929-933

  Hald, Jannie D ^a   Evangelou, Evangelos ^b,c   Langdahl, Bente L ^a   Ralston, Stuart H ^d  

^a AARHUS UNIVERSITY HOSPITAL   (Denmark)

^b UNIVERSITY OF IOANNINA   (Greece)

^c IMPERIAL COLLEGE LONDON   (United Kingdom)

^d UNIVERSITY OF EDINBURGH   (United Kingdom)

Author keywords

Bisphosphonates; Fracture risk; Osteogenesis imperfecta

Indexed keywords

BISPHOSPHONIC ACID DERIVATIVE; PLACEBO;

ARTICLE; BONE DENSITY; FOLLOW UP; FRACTURE; HUMAN; LONG TERM CARE; META ANALYSIS; OSTEOGENESIS IMPERFECTA; QUALITY CONTROL; RANDOMIZED CONTROLLED TRIAL (TOPIC); RISK ASSESSMENT; TREATMENT OUTCOME; TREATMENT RESPONSE; COMPLICATION; FRACTURES, BONE;

DIPHOSPHONATES; FRACTURES, BONE; HUMANS; OSTEOGENESIS IMPERFECTA; PLACEBOS; RANDOMIZED CONTROLLED TRIALS AS TOPIC;

EID: 84927740769     PISSN: 08840431     EISSN: 15234681     Source Type: Journal    
DOI: 10.1002/jbmr.2410     Document Type: Article

References (27)

1. Cundy T,. Recent advances in osteogenesis imperfecta. Calcif Tissue Int. 2012; 90: 439-449.
2. Sillence DO, Rimoin DL,. Classification of osteogenesis imperfecta [letter]. Lancet. 1978; 1: 1041-1042.
3. van Dijk FS, Nesbitt IM, Zwikstra EH, et al. PPIB mutations cause severe osteogenesis imperfecta. Am J Hum Genet. 2009; 85: 521-527.
4. Cho TJ, Lee KE, Lee SK, et al. A single recurrent mutation in the 5'-UTR of IFITM5 causes osteogenesis imperfecta type V. Am J Hum Genet. 2012; 91: 343-348.
5. Shaheen R, Alazami AM, Alshammari MJ, et al. Study of autosomal recessive osteogenesis imperfecta in Arabia reveals a novel locus defined by TMEM38B mutation. J Med Genet. 2012; 49: 630-635.
6. Shaheen R, Al-Owain M, Faqeih E, et al. Mutations in FKBP10 cause both Bruck syndrome,isolated osteogenesis imperfecta in humans. Am J Med Genet A. 2011; 155A: 1448-1452.
7. Cabral WA, Chang W, Barnes AM, et al. Prolyl 3-hydroxylase 1 deficiency causes a recessive metabolic bone disorder resembling lethal/severe osteogenesis imperfecta. Nat Genet. 2007; 39: 359-365.
8. Barnes AM, Chang W, Morello R, et al. Deficiency of cartilage-associated protein in recessive lethal osteogenesis imperfecta. N Engl J Med. 2006; 355: 2757-2764.
9. Morello R, Bertin TK, Chen Y, et al. CRTAP is required for prolyl 3-hydroxylation and mutations cause recessive osteogenesis imperfecta. Cell. 2006; 127: 291-304.
10. Pyott SM, Tran TT, Leistritz DF, et al. WNT1 mutations in families affected by moderately severe and progressive recessive osteogenesis imperfecta. Am J Hum Genet. 2013; 92: 590-597.
11. Phillipi CA, Remmington T, Steiner RD,. Bisphosphonate therapy for osteogenesis imperfecta. Cochrane Database Syst Rev. 2008; CD005088.
12. Sakkers R, Kok D, Engelbert R, et al. Skeletal effects and functional outcome with olpadronate in children with osteogenesis imperfecta: a 2-year randomised placebo-controlled study. Lancet. 2004; 363: 1427-1431.
13. Bishop N, Adami S, Ahmed SF, et al. Risedronate in children with osteogenesis imperfecta: a randomised, double-blind, placebo-controlled trial. Lancet. 2013; 382: 1424-1432.
14. Bishop N, Harrison R, Ahmed F, et al. A randomized, controlled dose-ranging study of risedronate in children with moderate and severe osteogenesis imperfecta. J Bone Miner Res. 2010; 25: 32-40.
15. Ward LM, Rauch F, Whyte MP, et al. Alendronate for the treatment of pediatric osteogenesis imperfecta: a randomized placebo-controlled study. J Clin Endocrinol Metab. 2011; 96: 355-364.
16. Chevrel G, Schott AM, Fontanges E, et al. Effects of oral alendronate on BMD in adult patients with osteogenesis imperfecta: a 3-year randomized placebo-controlled trial. J Bone Miner Res. 2006; 21: 300-306.
17. Letocha AD, Cintas HL, Troendle JF, et al. Controlled trial of pamidronate in children with types III and IV osteogenesis imperfecta confirms vertebral gains but not short-term functional improvement. J Bone Miner Res. 2005; 20: 977-986.
18. Jadad AR, Moore RA, Carroll D, et al. Assessing the quality of reports of randomized clinical trials: is blinding necessary? Control Clin Trials. 1996; 17: 1-12.
19. Gatti D, Antoniazzi F, Prizzi R, et al. Intravenous neridronate in children with osteogenesis imperfecta: a randomized controlled study. J Bone Miner Res. 2005; 20: 758-763.
20. Rauch F, Munns CF, Land C, Cheung M, Glorieux FH,. Risedronate in the treatment of mild pediatric osteogenesis imperfecta: a randomized placebo-controlled study. J Bone Miner Res. 2009; 24: 1282-1289.
21. Bishop N, Harrison R, Ahmed F, et al. A randomised controlled dose-ranging study of risedronate in children with moderate and severe osteogenesis imperfecta. J Bone Miner Res. 2010; 25: 32-40.
22. Bradbury LA, Barlow S, Geoghegan F, et al. Risedronate in adults with osteogenesis imperfecta type I: increased bone mineral density and decreased bone turnover, but high fracture rate persists. Osteoporos Int. 2012; 23: 285-294.
23. Glorieux FH, Bishop NJ, Plotkin H, Chabot G, Lanoue G, Travers R,. Cyclic administration of pamidronate in children with severe osteogenesis imperfecta. N Engl J Med. 1998; 339: 947-952.
24. Sambrook P, Cooper C,. Osteoporosis. Lancet. 2006; 367: 2010-2018.
25. Abrahamsen B,. Adverse effects of bisphosphonates. Calcif Tissue Int. 2010; 86: 421-435.
26. Hennedige AA, Jayasinghe J, Khajeh J, Macfarlane TV,. Systematic review on the incidence of bisphosphonate related osteonecrosis of the jaw in children diagnosed with osteogenesis imperfecta. J Oral Maxillofac Res. 2013; 4: e1.
27. Nicolaou N, Agrawal Y, Padman M, Fernandes JA, Bell MJ,. Changing pattern of femoral fractures in osteogenesis imperfecta with prolonged use of bisphosphonates. J Child Orthop. 2012; 6: 21-27.